DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Post-Radioiodine Graves' Management: The PRAGMA-Study

Information source: Newcastle-upon-Tyne Hospitals NHS Trust
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Graves' Disease

Phase: N/A

Status: Recruiting

Sponsored by: Newcastle-upon-Tyne Hospitals NHS Trust

Summary

Thyroid dysfunction following radioiodine for Graves' disease is common, potentially detrimental and avoidable. A variety of clinical strategies are employed in the post-radioiodine era util the patient is on a stable thyroid hormone replacement regimen, which include the use of anti-thyroid drugs, antithyroid drugs with thyroxine, early thyroxine replacement and watchful monitoring until the onset of hypothyroidism. Which of these is most effective in avoiding dysthyroidism, is unknown. This study aims to address this lack of evidence. It will focus on Graves' disease as this is the commonest cause of thyrotoxicosis and the commonest indication for RI therapy. It will provide an insight into potential strategies for improving important clinical outcomes.

Clinical Details

Official title: POST-RADIOIODINE GRAVES' MANAGEMENT

Study design: Observational Model: Cohort, Time Perspective: Retrospective

Primary outcome: Incidence of dysthyroidism post-RI between different post-RI management strategies employed by clinicians in the UK

Secondary outcome:

Graves orbitopathy

weight gain

progression of Graves' orbitopathy

patient satisfaction

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Out-patients 18 years of age or over, who have given written informed consent to

participate in the study

- Diagnosed with Graves' disease

- Received radioiodine for treatment of Graves' disease

- Had a minimum of 12 months follow-up after RI

- Most recent RI dose 5 years ago or less at the time of enrollment

Exclusion Criteria:

- Patients unable to give informed consent

- Age 17 years or younger

- Cause of thyrotoxicosis other than Graves' disease

- Patients who have had more than one dose of radioiodine can only be included in the

study once, using data pertaining to their most recent treatment episode.

- Patients who might not adequately understand verbal explanations or written

information given in English, or who have special communication needs

Locations and Contacts

Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4LP, United Kingdom; Not yet recruiting
Petros Perros, BSc, MBBS, MD, Phone: 0044191 2820950, Email: petros.perros@nuth.nhs.uk
Petros Perros, BSc, MBBS, MD, Principal Investigator

Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England NE3 4HD, United Kingdom; Recruiting
Petros Perros, MBBS, Phone: 441912852786, Email: petros.perros@ncl.ac.uk
Petros Perros, MBBS, Principal Investigator

Additional Information

Starting date: March 2013
Last updated: June 20, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017